首页 | 本学科首页   官方微博 | 高级检索  
     


High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
Authors:Cuiling Ding  Wanda Tang  Binghui Xia  Haoran Peng  Yan Liu  Jiaqi Wang  Xu Zheng  Yangang Liu  Lanjuan Zhao  Yanhua He  Zhongtian Qi  Hao Ren  Hailin Tang  Ping Zhao
Affiliation:Department of Microbiology, Navy Medical University, Shanghai 200433, China; (C.D.); (W.T.); (B.X.); (H.P.); (Y.L.); (J.W.); (X.Z.); (Y.L.); (L.Z.); (Y.H.); (Z.Q.); (H.R.)
Abstract:
The emergence of significant arboviruses and their spillover transmission to humans represent a major threat to global public health. No approved drugs are available for the treatment of significant arboviruses in circulation today. The repurposing of clinically approved drugs is one of the most rapid and promising strategies in the identification of effective treatments for diseases caused by arboviruses. Here, we screened small-molecule compounds with anti-tick-borne encephalitis virus, West Nile virus, yellow fever virus and chikungunya virus activity from 2580 FDA-approved drugs. In total, 60 compounds showed antiviral efficacy against all four of the arboviruses in Huh7 cells. Among these compounds, ixazomib and ixazomib citrate (inhibitors of 20S proteasome β5) exerted antiviral effects at a low-micromolar concentration. The time-of-drug-addition assay suggested that ixazomib and ixazomib citrate disturbed multiple processes in viruses’ life cycles. Furthermore, ixazomib and ixazomib citrate potently inhibited chikungunya virus replication and relieved virus-induced footpad swelling in a mouse model. These results offer critical information which supports the role of ixazomib as a broad-spectrum agent against arboviruses.
Keywords:arboviruses   ixazomib   broad-spectrum antivirals screening   FDA-approved drugs
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号